Long-acting injectable antipsychotics: what, when, and how – Addendum

Leslie Citrome

doi:10.1017/S1092852921000456

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

González-Rodríguez, Alexandre Monreal, José A. and V. Seeman, Mary 2022. Factors Influencing Adherence to Antipsychotic Medications in Women with Delusional Disorder: A Narrative Review. Current Pharmaceutical Design, Vol. 28, Issue. 15, p. 1282.

Lähteenvuo, Markku Paljärvi, Tapio Tanskanen, Antti Taipale, Heidi and Tiihonen, Jari 2023. Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study . The British Journal of Psychiatry, Vol. 223, Issue. 4, p. 456.

Rosenheck, Robert Anand, Sonia T. Kurtz, Stephen G. Hau, Cynthia Smedberg, Diane Pontzer, James F. Ferguson, Ryan E. and Davis, Cynthia R. 2023. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials, Vol. 24, Issue. 1,

Rediger, Katherine 2025. Improving Schizophrenia Treatment Through Collaborative Care: Use of Long-Acting Injectable Antipsychotics. Journal of Psychosocial Nursing and Mental Health Services, Vol. 63, Issue. 11, p. 10.

Citrome, Leslie Correll, Christoph Cutler, Andrew Dunbar, Martin Hoberg, Amber Hopkinson, Craig Mattingly, Gregory McGrory, James Rege, Bhaskar Weiden, Peter and McDonnell, David 2025. Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia. Neuropsychiatric Disease and Treatment, Vol. Volume 21, Issue. , p. 575.

Sun, Christina Temelie, Andreea Goulding, Hannah Clark, Christine Yabs, Melanie and Fabian, Tanya 2025. Long-Acting Injectable Antipsychotic Initiation in Child and Adolescent Patients with Psychiatric Disorders. Journal of Child and Adolescent Psychopharmacology, Vol. 35, Issue. 2, p. 80.

Citrome, Leslie Nagaraj, Nayana Traverso, Giovanni Dumas, Todd and Scranton, Richard 2025. Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial. The Lancet Psychiatry, Vol. 12, Issue. 7, p. 504.

Tumwebaza, John Martin Bukke, Sarad Pawar Naik Narapureddy, Bayapa Reddy Kabera, Radiana Makuza Sebisaalu, Joel Abubakar, Amina Kitheka, Patrick Muasya Nimusiima, Godwin Mohamed, Awad Osman Abdalla Muwanguzi, Moses Ashaba, Scholastic Yadesa, Tadele Mekuriya and Fadare, Joseph Olusesan 2026. Prevalence, severity and predictors of Antipsychotic-Related Adverse Drug Reactions at the Psychiatry Clinic of a Regional Referral Hospital in Uganda. PLOS One, Vol. 21, Issue. 8, p. e0356000.

Article contents

Long-acting injectable antipsychotics: what, when, and how – Addendum

Abstract

Information

References

This addendum applies to the following article(s):

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Long-acting injectable antipsychotics: what, when, and how – Addendum

Abstract

Information

References

This addendum applies to the following article(s):

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests